ACADIA Pharmaceuticals Inc.
ACADHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, ACADIA Pharmaceuticals Inc. focuses on Biotechnology services and products. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. At a $4.38B market cap, ACADIA Pharmaceuticals Inc. ranks as a mid-cap company within healthcare. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Market Cap
$4.38B
Beta
0.80
P/E (TTM)
11.58
P/E (Fwd)
28.74
EPS (TTM)
$2.21
EPS (Fwd)
$0.89
ROE
37.3%
ROA
3.7%
Cash
$851.5M
Total Debt
$50.8M
Free CF
$154.1M
52W Change
13.5%
Annual Financials
Cash vs Debt
With $851.5M in cash and $50.8M in debt, ACAD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $154.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 37.3% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.7% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $517.2M (2022) to $1.07B (2025), reflecting a 107% increase over the period.
With cash comfortably exceeding debt, ACAD has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for ACADIA Pharmaceuticals Inc. and its sector.